MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14740/jh2149

Медицинская библиотека · Journal of hematology · 2025

Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma.

Chen Shi Lv, Feng Yu, Xue Jiao, Wang Shan, Wu Shao Ling

СтатьяПеревод в очереди

Аннотация

BACKGROUND

This study aimed to investigate the efficacy and safety of orelabrutinib monotherapy in Chinese patients with marginal zone B-cell lymphoma (MZL).

METHODS

We conducted a retrospective analysis of MZL patients treated with orelabrutinib monotherapy (n = 30) or rituximab/rituximab plus bendamustine (R/BR) (n = 81) at the Affiliated Hospital of Qingdao University from January 1, 2019, to December 31, 2023. Orelabrutinib monotherapy was assigned to the experimental group. Propensity score matching (PSM) was applied to match 30 MZL patients treated with the R/BR regimen as a control group, comparing the efficacy and safety between the two groups.

RESULTS

In both the orelabrutinib group and the control group, patients who developed relapsed or refractory (R/R) disease after non-rituximab/rituximab-based chemotherapy (non-R/R-CT) therapies (including anti-infective treatment and localized radiotherapy) achieved clinical responses. For 17 patients with R/R disease following R/R-CT treatment, no statistically significant differences were observed between the orelabrutinib group and the BR group in disease control rate (DCR) (82.35% vs. 88.23%, P = 1.00), overall response rate (ORR) (64.70% vs. 76.47%, P = 0.70), and complete response (CR) (17.64% vs. 29.41%, P = 0.68). There was no statistically significant difference in 1-year event-free survival (EFS) (86.66% (95% confidence interval (CI): 68.27 - 94.77) vs. 83.33% (95% CI: 64.49 - 92.70), P = 0.66). Hematologic adverse events (66.66% vs. 86.66%, P = 0.10), lymphopenia (6.66% vs. 40.00%, P < 0.01), and grade 3/4 adverse events (10.00% vs. 33.33%, P = 0.03) were all lower in the orelabrutinib group compared to the control group. Neither group had patients who discontinued treatment due to adverse reactions.

CONCLUSION

Orelabrutinib monotherapy in MZL possesses favorable efficacy and safety in our study. Given the limited sample size, further clinical research with larger cohorts and extended follow-up is necessary.

Для цитирования: Chen Shi Lv, Feng Yu, Xue Jiao, Wang Shan, Wu Shao Ling. Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma.. Journal of hematology. 2025. DOI: 10.14740/jh2149.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.